Study shows Purdue’s switch to ‘abuse-deterrent’ OxyContin helped drive a spike in hepatitis C infections

When Purdue Pharma reformulated its signature pain drug OxyContin in 2010, its aim was to make the pill “abuse-deterrent.” But the change may have had an unanticipated and disastrous public health impact, according to a new study: accelerating a nationwide spike in hepatitis C infections.